由于竞争、处方增长放缓和新的联邦定价规则,美国肥胖症药品价格不断下跌,对早先的市场预测提出了挑战。 U.S. obesity drug prices are dropping due to competition, slowing prescription growth, and new federal pricing rules, challenging earlier market forecasts.

美国肥胖症药品价格因竞争和非专利药物而下降,令人怀疑2030年代全球市场预测值为1 500亿美元,分析家将高峰增长率改为2035年。 U.S. obesity drug prices are falling due to competition and generics, casting doubt on the $150 billion global market forecast by the 2030s, with analysts revising peak growth to 2035. 尽管最初对Wegovy和Zepbound的需求量很大,但新处方在诺沃·诺迪斯克新药片的推动下增长缓慢。 Despite strong initial demand for Wegovy and Zepbound, new prescriptions are growing slowly, driven by Novo Nordisk’s new pill. 同时,Eli Lilly和Novo Nordisk报告说,在Medicare公司共同付费协议和联邦定价规则的定价压力下,销售量强劲。 Meanwhile, Eli Lilly and Novo Nordisk report strong sales amid pricing pressures from Medicare copay agreements and federal pricing rules. 专利到期、生物类比竞争不断上升以及新的联邦定价框架正在重塑该行业,推动公司转向生物学,并加速并购活动。 Patent expirations, rising biosimilar competition, and new federal pricing frameworks are reshaping the industry, pushing companies toward biologics and accelerating M&A activity.